Alx Oncology Holdings (ALXO) Cash from Financing Activities (2019 - 2026)

Alx Oncology Holdings (ALXO) has 8 years of Cash from Financing Activities data on file, last reported at $139.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 214661.54% year-over-year to $139.6 million; the trailing twelve-month figure through Mar 2026 stood at $139.9 million (up 403.28% YoY), and the FY2025 full-year result was $362000.0, down 98.83% from the prior year.
• Cash from Financing Activities advanced to $139.6 million in Q1 2026, from $678000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $139.6 million in Q1 2026 to a low of -$222000.0 in Q2 2025.
• A 5-year average of $14.1 million and a median of $328000.0 in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities slumped 233.75% in 2023 and soared 214661.54% in 2026, its largest moves.
• Tracing ALXO's Cash from Financing Activities over 5 years: stood at $9.5 million in 2022, then soared by 523.19% to $59.2 million in 2023, then slumped by 99.45% to $328000.0 in 2024, then soared by 106.71% to $678000.0 in 2025, then jumped by 20489.23% to $139.6 million in 2026.
• Business Quant data shows ALXO's Cash from Financing Activities at $139.6 million in Q1 2026, $678000.0 in Q4 2025, and -$159000.0 in Q3 2025.